Next Article in Journal
Heart of the World’s Top Ultramarathon Runner—Not Necessarily Much Different from Normal
Previous Article in Journal
The Efficacy of Lactulose for the Treatment of Hyperammonemic Encephalopathy Due to Severe Heart Failure
Open AccessArticle

Circulating Anti-Sorting Nexins 16 Antibodies as an Emerging Biomarker of Coronary Artery Disease in Patients with Obstructive Sleep Apnea

1
Department of Respirology, Graduate School of Medicine, Chiba University, Chiba 260‐8670, Chiba, Japan
2
Fujikura Kasei Co.,Ltd., Minato-ku, Tokyo 105-0011, Japan
3
Research Center for Medical and Health Data Science, The Institute of Statistical Mathematics, Tokyo 190-8562, Japan
4
Department of Cardiovascular Medicine, Graduate School of Medicine, Chiba University, Chiba 260‐8670, Japan
5
Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba 260‐8670, Japan
6
Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba 260‐8670, Japan
*
Author to whom correspondence should be addressed.
Diagnostics 2020, 10(2), 71; https://doi.org/10.3390/diagnostics10020071
Received: 26 December 2019 / Revised: 17 January 2020 / Accepted: 25 January 2020 / Published: 27 January 2020
(This article belongs to the Special Issue Discovery of Antibody Biomarker)
Biomarkers are not available for monitoring the onset and progression of coronary artery disease (CAD) in patients with obstructive sleep apnea (OSA), a major risk factor for arteriosclerotic cardiovascular diseases. This study aimed to test for correlation between circulating anti-Sorting Nexins 16 antibody (SNX16-Ab) levels, CAD history and clinical parameters of patients with OSA. Sixty-four healthy donors, 82 adults with OSA, and 96 with acute coronary syndrome (ACS) were studied. Serum samples were collected at diagnostic polysomnography in the OSA group or at the disease onset in the ACS group. Serum SNX16-Ab levels were measured by amplified luminescence proximity homogeneous assay (AlphaLISA), and correlation between SNX16-Ab levels and clinical parameters was analyzed. SNX16-Ab levels and apnea-hypopnea index (AHI) were weakly correlated. Additionally, logistic regression analyses of OSA group identified that elevated SNX16-Ab level associated with the history of CAD. Circulating SNX16-Ab could increase during CAD pathogenesis in patients with OSA. Further prospective studies are required to prove the predictive potential of SNX16-Ab level in CAD onset of patients with OSA.
Keywords: atherosclerosis; autoantibody; biomarker; coronary artery; obstructive sleep apnea atherosclerosis; autoantibody; biomarker; coronary artery; obstructive sleep apnea
MDPI and ACS Style

Katsumata, Y.; Terada, J.; Matsumura, T.; Koshikawa, K.; Sakao, S.; Tomiyoshi, G.; Shinmen, N.; Nakamura, R.; Kuroda, H.; Nagashima, K.; Kobayashi, Y.; Kobayashi, E.; Iwadate, Y.; Zhang, X.-M.; Hiwasa, T.; Tatsumi, K. Circulating Anti-Sorting Nexins 16 Antibodies as an Emerging Biomarker of Coronary Artery Disease in Patients with Obstructive Sleep Apnea. Diagnostics 2020, 10, 71.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop